Marker Therapeutics, Inc. (NASDAQ:MRKR) Receives $11.25 Consensus Target Price from Brokerages

Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) have been given an average rating of “Hold” by the four brokerages that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $10.00.

A number of research analysts recently issued reports on the stock. Zacks Research cut shares of Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. UBS Group reiterated a “buy” rating on shares of Marker Therapeutics in a report on Monday, December 8th. Wall Street Zen upgraded Marker Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. HC Wainwright began coverage on Marker Therapeutics in a research note on Monday, December 8th. They set a “buy” rating and a $10.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Marker Therapeutics in a research note on Friday.

Institutional Trading of Marker Therapeutics

Several institutional investors have recently bought and sold shares of the company. Jane Street Group LLC bought a new stake in Marker Therapeutics during the 2nd quarter valued at about $33,000. Two Sigma Investments LP bought a new position in shares of Marker Therapeutics in the third quarter worth approximately $33,000. Virtu Financial LLC bought a new position in shares of Marker Therapeutics in the third quarter worth approximately $25,000. Boyer Financial Services Inc. purchased a new stake in shares of Marker Therapeutics during the fourth quarter valued at approximately $57,000. Finally, Geode Capital Management LLC increased its position in shares of Marker Therapeutics by 35.3% during the fourth quarter. Geode Capital Management LLC now owns 130,344 shares of the company’s stock valued at $194,000 after acquiring an additional 34,028 shares in the last quarter. 22.39% of the stock is owned by hedge funds and other institutional investors.

Marker Therapeutics Stock Up 4.8%

MRKR opened at $1.30 on Wednesday. The stock has a market cap of $21.67 million, a PE ratio of -1.53 and a beta of 1.42. The business has a 50 day moving average of $1.51 and a 200-day moving average of $1.32. Marker Therapeutics has a 52 week low of $0.81 and a 52 week high of $4.07.

Marker Therapeutics (NASDAQ:MRKR) last issued its quarterly earnings results on Wednesday, March 18th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.17. The company had revenue of $1.10 million for the quarter, compared to analysts’ expectations of $0.68 million. Marker Therapeutics had a negative return on equity of 80.86% and a negative net margin of 343.03%. Equities analysts anticipate that Marker Therapeutics will post -0.65 EPS for the current year.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.